NCCM
ACHN

Nine Chapters Capital Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Nine Chapters Capital Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-14,600
Closed -$61K – 228
2017
Q1 		$61K Buy
+14,600
New +$60.6K 0.08% 213
2015
Q4 		– Sell
-36,000
Closed -$249K – 732
2015
Q3 		$249K Buy
36,000
+8,600
+31% +$70.1K 0.02% 770
2015
Q2 		$243K Buy
+27,400
New +$259K 0.02% 768
2015
Q1 		– Sell
-60,600
Closed -$742K – 1213
2014
Q4 		$742K Buy
+60,600
New +$740K 0.06% 418
2014
Q3 		– Sell
-26,700
Closed -$202K – 1251
2014
Q2 		$202K Buy
26,700
+12,000
+82% +$47.9K 0.02% 829
2014
Q1 		$48K Buy
+14,700
New +$51.4K 0.01% 780

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Nine Chapters Capital Management's ACHN Position: Q2 2017 in Review

Nine Chapters Capital Management sold out of Achillion Pharmaceuticals (ACHN) in Q2 2017, closing a stake of 14,600 shares — an estimated $61K sold.

Nine Chapters Capital Management first reported a position in ACHN in Q1 2014 and held it in 6 quarters. The position peaked at $742K in Q4 2014. 129 funds tracked by Wall St. Rank hold ACHN as of Q2 2017.

  • Nine Chapters Capital Management reported no remaining Achillion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Nine Chapters Capital Management sold 14,600 Achillion Pharmaceuticals shares in Q2 2017, an estimated $61K.
  • Nine Chapters Capital Management first reported a position in Achillion Pharmaceuticals in Q1 2014 and held it in 6 quarters.
  • Nine Chapters Capital Management's Achillion Pharmaceuticals position peaked at $742K in Q4 2014.
  • 129 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2017.

Based on Nine Chapters Capital Management's 13F filing for Q2 2017, filed 31 Jul 2017.